ReviewInternational journal of molecular sciences2026
Advanced Drug Delivery in Pediatric Neurology: Developmental Barriers, Nanocarrier Strategies, and Translational Challenges.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treating neurological disorders in children is particularly challenging due to the dynamic maturation of the developing brain, age-dependent pharmacokinetics, and evolving structural and functional properties of the blood-brain barrier (BBB). This review explores the latest advances in drug-delivery systems tailored for pediatric neurology, emphasizing strategies to address physiological and developmental determinants of treatment response across infancy, childhood, and adolescence. The paper begins by outlining the distinct challenges of drug delivery in children, focusing on BBB maturation, transporter expression, metabolic capacity, and neurodevelopmental vulnerability. Emerging delivery systems, such as liposomes, polymeric nanoparticles, dendrimers, micelles, gold nanoparticles, and gene- and RNA-based vectors, are further reviewed in relation to major pediatric neurological conditions. These platforms demonstrate promise in enhancing drug bioavailability, targeting specific brain regions, and minimizing systemic toxicity. This paper also covers important safety, regulatory, and ethical considerations in pediatric populations, with a focus on the need for age-appropriate design and thorough clinical validation. Concluding with emerging trends and future directions, this work serves as a comprehensive resource for advancing pediatric neurological therapeutics through state-of-the-art drug delivery technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.